AB0574 UVEITIS IN 406 PATIENTS WITH PSORIATIC ARTHRITIS. STUDY FROM A SINGLE UNIVERSITARY CENTER

医学 葡萄膜炎 银屑病性关节炎 骶髂关节炎 HLA-B27 皮肤病科 流行病学 强直性脊柱炎 内科学 眼科 银屑病 外科 免疫学 人类白细胞抗原 抗原
作者
A. De Vicente-Delmás,L. Sánchez-Bilbao,D. Martínez-López,I. González-Mazón,V. Calvo-Río,Natalia García,Natalia Palmou‐Fontana,Miguel Á. González‐Gay,Ricardo Blanco
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:80 (Suppl 1): 1324-1325
标识
DOI:10.1136/annrheumdis-2021-eular.1873
摘要

Background: Uveitis is an extraarticular manifestation of psoriatic arthritis (PsA) and it has been described as the most frequent ocular manifestation in PsA. Uveitis in PsA has been described to be more likely insidious in onset, continuous, posterior, and active bilaterally compared with uveitis in patients with Spondyloarthritis (Paiva ES, et al. Ann Rheum Dis. 2000;59: 67-7 ). Anti-TNF agents, especially monoclonal antibodies have been effective in prevention and treatment of refractory non-infectious uveitis. Objectives: Our aim was to assess a ) epidemiology and clinical features of uveitis associated to PsA, b ) to compare patients who developed uveitis and those who did not and c ) its relationship with biological treatment used in PsA. Methods: We conducted a cross-sectional study of 406 patients with PsA from a single reference University Hospital with: a ) PsA classified by CASPAR criteria and, b ) diagnosis of uveitis by expert ophthalmologists. Demographic features, clinical findings, complementary tests, occurrence of other extraarticular manifestations and treatment were recorded. Results: We studied 406 (202 women/204 men) patients with PsA, mean age of 46.3±12.3 years. Uveitis was observed in 20 (12 women/8 men) of 406 patients (prevalence 4.9%); mean age of 43.1±14.5 years. Uveitis was most frequently anterior (80%), unilateral (80%), of acute onset (100%), and recurrent (50%). In the comparative study between patients who developed uveitis and who did not (Table 1), in patients with uveitis was more frequent the presence of HLA-B27 positive (45%), sacroiliitis in MRI (25%), ocular surface pathology (10%), and higher mean PsAID score (4.8±2.5). Ten (50%) patients with PsA related uveitis received biological therapy, 12 (60%) of the treatments were anti-TNF monoclonal antibodies and 1 (5%) was etanercept. The 2 (10%) remaining therapies were other biological therapy non anti-TNF (Figure 1). Figure 1. Biologic immunosuppressive drugs in PsA patients related uveitis. Conclusion: Uveitis was observed in 4.9% of patients with PsA.Most of the PsA related uveitis had an acute onset with anterior and unilateral pattern. HLA-B27 positive, presence of sacroiliitis on MRI and ocular surface pathology were more frequent in patients who developed uveitis. PsAID score is higher in patients with uveitis. Table 1. General features of 406 patients with PsA. Comparison between with and without uveitis. Overall (n= 406 ) Uveitis (n= 20 ) Non uveitis (n= 386 ) p Main general features Age, years, mean±SD 46.3±12.3 43.1±14.5 46.5±12.2 0.225 Sex, women/men, N (% of women) 202/204(49.8) 12/8 (60) 218/168 (56.5) 0.757 HLAB-27 positive, N (%) 38(9.4) 9 (45) 29 (7.5) 0.000* PsA pattern Axial pattern, N (%) 48 (11.8) 4 (20) 44 (11.4) 0.277 Peripheral pattern, N (%) 236 (58.1) 12 (60) 224 (58) 0.862 Mixed pattern, N (%) 122 (30.1) 4 (20) 118 (30.6) 0.315 PsA Scores PsAID, mean±SD 3±2.4 4.8±2.5 2±2.6 0.003* Radiological features Sacroiliitis on MRI, N (%) 37 (9.1) 5 (25) 32 (8.3) 0.027* Other extraarticular manifestations Inflammatory bowel disease, N (%) 21 (5.2) 2 (10) 19 (4.9) 0.277 Ocular surface pathology, N (%) 5 (1.2) 2 (10) 3 (0.8) 0.021* Biologic treatments bDMARDs, N (%) 280 (68.9) 15 (75) 265 (68.7) 0.550 Etanercept 31 (7.6) 1 (5) 30 (7.8) 0.999 TNFi monoclonal antibodies 160 (39.4) 12 (60) 148 (38.3) 0.053 Disclosure of Interests: A. De Vicente-Delmás: None declared., Lara Sanchez-Bilbao: None declared., David Martínez-López: None declared., Iñigo González-Mazón: None declared., Vanesa Calvo-Río Speakers bureau: AbbVie, Lilly, Celgene, Grünenthal and UCB Pharma, Grant/research support from: MSD and Roche, Nuria Barroso García: None declared., Natalia Palmou-Fontana Speakers bureau: Celgene, AbbVie, Lilly, Miguel A González-Gay Speakers bureau: Pfizer, Abbvie, MSD, Grant/research support from: Pfizer, Abbvie, MSD, Ricardo Blanco Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD, Grant/research support from: AbbVie, MSD, and Roche.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI65的应助被ben采纳,获得10
1秒前
科研通AI65的应助被Code_king采纳,获得10
1秒前
syvshc的应助被Code_king采纳,获得10
1秒前
寂寞的小鱼的应助被Code_king采纳,获得10
2秒前
2秒前
4秒前
000000发布了新的文献求助10
5秒前
一百八完成签到,获得积分10
6秒前
7秒前
柔弱的笑蓝完成签到,获得积分10
8秒前
斯文败类的应助被cyu采纳,获得10
8秒前
刘宁完成签到 ,获得积分10
8秒前
yyy关注了科研通微信公众号
9秒前
顺心卿发布了新的文献求助10
10秒前
10秒前
11秒前
落单的情绪完成签到 ,获得积分10
12秒前
13秒前
南方三炁火德星君完成签到,获得积分10
13秒前
13秒前
14秒前
甜蜜的依玉完成签到,获得积分10
14秒前
15秒前
15秒前
李健的应助被白羽采纳,获得10
15秒前
万能图书馆的应助被洗衣机采纳,获得10
15秒前
我是老大的应助被小张医生采纳,获得10
16秒前
16秒前
rock发布了新的文献求助10
16秒前
17秒前
xsc完成签到,获得积分10
17秒前
JeanetteJin发布了新的文献求助50
17秒前
飞行员发布了新的文献求助10
17秒前
18秒前
懒羊羊完成签到 ,获得积分10
18秒前
烟花的应助被王木木采纳,获得10
19秒前
19秒前
小可爱完成签到 ,获得积分10
19秒前
21秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177654
求助须知:如何正确求助?哪些是违规求助? 9568503
关于积分的说明 21799551
捐赠科研通 7772253
什么是DOI,文献DOI怎么找? 3432428
关于科研通互助平台的介绍 2556594
邀请新用户注册赠送积分活动 2478011